top of page
Profile
Join date: Jan 17, 2025
About
0 likes received
0 comments received
0 best answers
Biparatopic receptor-based bispecific ADCs (Antibody-Drug Conjugates) are an advanced class of therapeutics designed to target and destroy cancer cells with high specificity and potency. They integrate several cutting-edge biological technologies, including bispecific antibodies, biparatopic targeting, and the cytotoxic effects of ADCs.
Smith Gemini
More actions
bottom of page